A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Pharmacokinetics of low doses of colchicine in the leukocytes of Japanese healthy individuals. | LitMetric

Pharmacokinetics of low doses of colchicine in the leukocytes of Japanese healthy individuals.

Transl Clin Pharmacol

Department of Clinical Pharmacology and Therapeutics, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan.

Published: December 2023

AI Article Synopsis

  • Colchicine has gained attention as an FDA-approved anti-inflammatory for cardiovascular diseases, though its low dose of 0.5 mg can cause side effects.
  • The drug quickly leaves the bloodstream and enters leukocytes, which helps produce its anti-inflammatory effects.
  • This study explores how colchicine behaves in plasma and leukocytes after taking 0.5 mg and 0.25 mg doses, finding that it remains in leukocytes even at lower dosages, potentially reducing side effects.

Article Abstract

The venerable drug colchicine has garnered significant recent attention due to its endorsement by the United States Food and Drug Administration as an anti-inflammatory medication for cardiovascular diseases. However, the administration of this drug at its minimal available dose of 0.5 mg has been associated with certain adverse reactions. Once colchicine is administered, the drug disappears from blood in a short time and distributes in the leukocytes for a certain period of time that elicits anti-inflammatory effect. Consequently, an in-depth comprehension of the pharmacokinetics of lower dosages within leukocytes assumes important for its broader application in routine clinical contexts. In this study, we present a comprehensive analysis of the pharmacological disposition of colchicine in the plasma, polymorphonuclear leukocytes, and mononuclear leukocytes among healthy Japanese male subjects, following both single and multiple oral administrations of 0.5 mg and 0.25 mg doses of colchicine. Our investigation reveals that colchicine persists within leukocyte populations even when administered at reduced dosages. The findings herein hold promise for mitigating the adverse effects associated with its use in the treatment of inflammatory cardiovascular disorders.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10772056PMC
http://dx.doi.org/10.12793/tcp.2023.31.e19DOI Listing

Publication Analysis

Top Keywords

doses colchicine
8
colchicine
6
leukocytes
5
pharmacokinetics low
4
low doses
4
colchicine leukocytes
4
leukocytes japanese
4
japanese healthy
4
healthy individuals
4
individuals venerable
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!